ArticleBiomaterials2019
Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme.
Article in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.Pharmacological research · 2021Pooled it
- Nano-Polymers as Cas9 Inhibitors.Polymers · 2025Article
- New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer cell international · 2024Review
- Designing Gold Nanoparticles for Precise Glioma Treatment: Challenges and Alternatives.Materials (Basel, Switzerland) · 2024Review
- Targeted Boron Neutron Capture Therapy Using Polymalic Acid Derived Nano-Boron to Treat Glioblastoma.Journal of oncology research and therapy · 2024Article
- Advances in Intraoperative Glioma Tissue Sampling and Infiltration Assessment.Brain sciences · 2023Review
- Neurotoxin-Derived Optical Probes for Biological and Medical Imaging.Molecular imaging and biology · 2023Review
- Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles.Cancers · 2023Review
- Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- New Boron Delivery Agents.Cancer biotherapy & radiopharmaceuticals · 2023Review
- Polymalic acid for translational nanomedicine.Journal of nanobiotechnology · 2022Review
- Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics.Pharmaceutics · 2022Review
- Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.Advanced drug delivery reviews · 2022Review
- GBP2 as a potential prognostic predictor with immune-related characteristics in glioma.Frontiers in genetics · 2022Article
- Small-Sized Co-Polymers for Targeted Delivery of Multiple Imaging and Therapeutic Agents.Nanomaterials (Basel, Switzerland) · 2021Review
- Construction of nanomaterials as contrast agents or probes for glioma imaging.Journal of nanobiotechnology · 2021Review
- Biosynthetic Polymalic Acid as a Delivery Nanoplatform for Translational Cancer Medicine.Trends in biochemical sciences · 2021Review
- Polyethylenimine-based theranostic nanoplatform for glioma-targeting single-photon emission computed tomography imaging and anticancer drug delivery.Journal of nanobiotechnology · 2020Article
- Image-guided tumor surgery: The emerging role of nanotechnology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Maximal surgical resection of glioma remains the single most effective treatment. Tools to guide the resection while avoiding removal of normal brain tissues can aid surgeons in achieving optimal results. One strategy to achieve this goal is to rely upon interoperative fluorescence staining of tumor cells in vivo, that can be visualized by the surgeon during resection. Towards this goal we have designed a biodegradable fluorescent mini nano imaging agent (NIA) with high specificity for U87MG glioma cells and previously unmet high light emission. The NIA is the conjugate of polymalic acid (PMLA) with chlorotoxin for tumor targeting, indocyanine green (ICG) for NIR fluorescence and the tri-leucin peptide as fluorescence enhancer. PMLA as a multivalent platform carries several molecules of ICG and the other ligands. The NIA recognizes multiple sites on glioma cell surface, demonstrated by the effects of single and combined competitors. Systemic IV injection into xenogeneic mouse model carrying human U87MG glioblastoma indicated vivid tumor cell binding and internalization of NIA resulting in intensive and long-lasting tumor fluorescence. The NIA is shown to greatly improve tumor removal supporting its utility in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.